New combo therapy targets Hard-to-Treat gut tumors

NCT ID NCT04750954

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug (peposertib) combined with a radioactive therapy (lutetium 177 dotatate) for people with a type of slow-growing gut and pancreas cancer called neuroendocrine tumors. The goal is to find the safest dose and see if the combination shrinks tumors better than the radioactive drug alone. About 29 adults with tumors that show up on a special scan will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE NEOPLASM

Contacts and locations

Show contact details

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.